Special Issue

Innate and Adaptive Immune Response against Human Herpesviruses

Message from the Guest Editors

Human herpesviruses (HHVs) are widely investigated as they mainly cause cutaneous disease and multiple pathologic abnormalities, and even have oncogenic properties. HHVs are known for their remarkable capacity to establish lifelong latent infections in human hosts, evading host immune surveillance through sophisticated mechanisms. The immune system employs both innate and adaptive immunity as fundamental defense mechanisms against infections. Innate immune cells utilize pattern recognition receptors (PRRs) to initiate an inflammatory response. On the other hand, adaptive immunity relies on the recognition of antigens by B and T cells, leading to the generation of specific immune responses. Among these responses, effector cells such as T helper cells and cytotoxic T lymphocytes play pivotal roles in effectively combating infections. By conducting specialized research in understanding immune system processes, ongoing research is necessary, we can bolster immune responses and develop more effective strategies to combat HHVs. To achieve these purposes, we cordially invite contributions of original articles or reviews.

Guest Editors

Dr. Chaoran Yin
Fox Chase Cancer Center, Philadelphia, PA, USA

Dr. Ting Zhang
Laboratory of Liver Transplantation, West China Hospital, Sichuan University, Chengdu, China

Deadline for manuscript submissions

closed (31 May 2024)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/182857

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI